New data from the FIELD study: protecting the diabetic eye

1. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; published on-line on 6 November. DOI: 10.1016/S0140-6736(07)61607-9.

2. www.idf.org. Accessed November 2007.

3. Gregg EW Gu Q , Cheng YJ et al. Mortality trends in men and women with diabetes, 1971–2000. Ann Intern Med2007;147:149–55.

4. Lipscombe LL Hux EJ. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study. Lancet2007;369:750–6.

5. Fong DS Aiello LP , Ferris FL , Klein R. Diabetic retinopathy. Diabetes Care2004;27:2540–53.

6. Wong TY Klein R , Islam FM et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol2006;141:446–55.

7. Cusick M Meleth AD , Agron E et al. Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care2005;28:617–25.

8. Nguyen TT Wong YT. Retinal vascular manifestations of metabolic disorders. Trends Endocrinol Metab2006;17:262–8.

9. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabetic Med2007;24:137–44.

10. Turner RC Cull CA , Frighi V , Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA1999;281:2005–12.

11. Gaede P Vedel P , Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med2003;348:383–93.

12. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol2003;136:122–35.

13. Cunningham ET Adamis AP , Altaweel M et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmol2005;112:1747–57.

14. Jorge R Costa RA , Calucci D et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina2006;26:1006–13.

15. Keech A Simes RJ , Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet2005;366:1849–61.

16. Burgess D Hunt D , Li LP et al. Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Circulation2007;116:II-838 (Abstract 3693).

17. ETDRS Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology1991;98:766–85.

18. ETDRS Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETRDS report number 10. Ophthalmology1991;98:786–806.

19. Meleth AD Agrón E , Chan CC et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci2005;46:4295–301.

20. Lyons TJ Jenkins AJ , Zheng D et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci2004;45:910–18.

21. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis2003;171:1–13.

22. Kim J Ahn JH , Yu YS et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Experimental Eye Res2007;84:886–93.

23. Goetze S Eilers F , Bungenstock A et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Comm2002;293:1431–7.

24. Demircan N Safran BG , Soylu M et al. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye2006;20:1366–9.

25. Ryan KE McCance DR , Powell L et al. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis2007;194:e123–e130.

26. Losada M Alio LJ. Malondialdehyde serum concentrations in type 1 diabetics with and without retinopathy. Documenta Ophthalmologica1997;93:223–9.

27. Skrha J Stulc T , Hilgertová J et al. Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. Eur J Pharmacol2004;493:183–9.

28. Chew EY Klein ML , Ferris FL 3rd et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol1996; 114:1079–84.

29. Zhang J McGwin G Association of statin use with the risk of developing diabetic retinopathy. Arch Ophthalmol2007;125:1096–9.

30. Ansquer JC Foucher C , Rattier S et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis2005;45:485–93.

31. Scott R d'Emden M , Best J et al. Features of metabolic syndrome identify individuals with type 2 diabetes mellitus at high risk for cardiovascular events and greater absolute benefits of fenofibrate. Circulation2007;116:II_838 (Abstract 3691).